GLP-1 Receptor Agonists and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
This cohort study aims to determine whether use of glucagon-like peptide 1 receptor agonists are associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer, among patients with metabolic dysfunction-associated steatotic liver disease.